Headshot of Joshua Friedman

Joshua Friedman, M.D., Ph.D., is Senior Vice President of Clinical Development. He is a physician-scientist with experience spanning drug discovery, translational science, and early and late clinical development. Most recently, Dr. Friedman served as Vice President and Head of Translational Science at Spark Therapeutics, a member of the Roche Group.

Prior to his position at Spark, Dr. Friedman was a Senior Director of Clinical Research at Alnylam Pharmaceuticals, where he was the clinical lead for early development of ALN-HSD for non-alcoholic steatohepatitis. Before joining Alnylam, Dr. Friedman served in various roles at Janssen Research and Development, including leading the Gastroenterology Translational Science function and serving as the clinical lead for the UNITI-2 study of STELARA®, an FDA-approved treatment for Crohn’s disease and ulcerative colitis.

Dr. Friedman received his B.S. in biochemistry from Harvard University, and M.D. and Ph.D. degrees from the University of Pennsylvania. He completed training in Pediatrics and Pediatric Gastroenterology at the Children’s Hospital of Philadelphia and was on the faculty at the University of Pennsylvania School of Medicine.